Concepts (109)
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Poorva Bindal's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Poorva Bindal has written about over time.
Androgen AntagonistsProstatic Neoplasms, Castration-ResistantAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungAgedAntibodies, Monoclonal, HumanizedRituximabHumansHemorrhageThrombosisMultiple MyelomaMedical MarijuanaMedical OncologyLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-mycImmunotherapy, AdoptiveHematologic NeoplasmsHemostasisLeukemia, Myeloid, Acute
To see the data from this visualization as text,
click here.
| Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
| Androgen Antagonists | 1 | 2018 | 2018 | August 2018 |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 2018 | August 2018 |
| Antineoplastic Agents, Immunological | 3 | 2018 | 2021 | August 2019 |
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 2021 | February 2020 |
| Aged | 11 | 2015 | 2025 | June 2020 |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 2021 | September 2020 |
| Rituximab | 2 | 2018 | 2023 | April 2021 |
| Humans | 19 | 2015 | 2025 | August 2021 |
| Hemorrhage | 3 | 2020 | 2024 | November 2021 |
| Thrombosis | 3 | 2020 | 2024 | November 2021 |
| Multiple Myeloma | 1 | 2023 | 2023 | May 2023 |
| Medical Marijuana | 2 | 2022 | 2025 | September 2023 |
| Medical Oncology | 2 | 2022 | 2025 | September 2023 |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 2023 | December 2023 |
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 2023 | December 2023 |
| Immunotherapy, Adoptive | 2 | 2023 | 2024 | December 2023 |
| Hematologic Neoplasms | 1 | 2024 | 2024 | April 2024 |
| Hemostasis | 1 | 2024 | 2024 | April 2024 |
| Leukemia, Myeloid, Acute | 2 | 2023 | 2025 | July 2024 |
To return to the timeline,
click here.